*For patients with COPD who seek symptom relief, YUPELRI is the first and only once-daily nebulized LAMA for a full 24 hours of lung function improvement.1
YUPELRI was studied in a two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies of once-daily YUPELRI in patients with moderate to very severe COPD. The primary endpoint was change from baseline in trough (predose ) FEV1 at day 85 vs placebo: YUPELRI demonstrated a statistically significant difference vs placebo in both studies. In addition, a prespecified exploratory analysis was performed using serial spirometry on a substudy population over 24 hours on days 84 /85, which showed consistent improvement in FEV1 versus placebo over 24 hours. See results here.

Up to 100% of patients with Medicare Part B are covered.† J-CODE J7677 Learn More
†This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.